Released Nov 12, 2021, after the close
10-Q filed Nov 12, 2021, 43 days after period end · 0001140361-21-037674
Q3 2021 · 10-Q
Revenue—
Net Income-$85.99M-$85.99M N/M vs Q3 2020N/M vs Q2 2021
EPS Diluted-$34.03-$34.03 N/M vs Q3 2020N/M vs Q2 2021
Operating Income-$86,276,000N/M
Operating Cash Flowderived-$6,422,000N/M
Free Cash Flowderived-$6,429,000N/M
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-Q.
Same quarter
| Metric | Q3 2021 | Q3 2020 | Q3 2019 | Q3 2018 |
|---|---|---|---|---|
| Revenue | — | $1.48M | $4.58M | $6.00M |
| Net Income | -$85.99M | -$2.02M | -$351.00K | $222.00K |
| EPS Diluted | -$34.03 | -$0.11 | -$0.12 | $0.08 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Ernexa Therapeutics Inc. · CIK 748592 · Engraved from SEC EDGAR